News

Zenas Biopharma has acquired global rights to develop the BTK inhibitor orelabrutinib to treat multiple sclerosis (MS) and other diseases. The deal with orelabrutinib’s developer, Innocare Pharma, includes rights to two other investigational therapies. Zenas will pay Innocare up to $100 million in cash and up to…

Roxy Murray was living up to being known as “The Multiple Sclerosis Fashionista” when she attended the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Barcelona, Spain, on a warm September afternoon. Murray, who has multiple sclerosis (MS) and lives in London, applies her…

Disability progression does not seem to worsen in women with multiple sclerosis (MS) after they undergo menopause, according to the largest study of its kind. Instead, other factors such as older age at MS onset, longer disease duration, and worse initial disability scores were associated with an increased risk…

The world’s largest meeting on multiple sclerosis (MS) has wrapped up for the year, and the National Multiple Sclerosis Society (NMSS) played a central role in many of the advances highlighted there. Nearly 10,000 people attended the 41st Congress of the European Committee for Treatment and Research in Multiple…

Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a low rate of disability progression in people with relapsing forms of multiple sclerosis (MS), with no new safety concerns reported. That’s according to new long-term data from the…

Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium continues to show a significant effect on disability worsening in people with progressive forms of multiple sclerosis (MS), even in those without signs of active inflammation in the brain, a group with limited treatment options. That’s according to new data…

Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional benefit in slowing disability progression compared with the standard regimen in people with primary progressive multiple sclerosis (PPMS). That’s according to top-line data from the Phase 3b GAVOTTE…

Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression for at least four years after starting on the approved therapy, according to new Phase 4 trial data. The results come from the CLARIFY-MS (NCT03369665) and MAGNIFY-MS (NCT03364036)…

Children and adolescents living with multiple sclerosis (MS) seem to benefit at least as much — and for some outcomes, significantly more — from Ocrevus (ocrelizumab) as from treatment with Gilenya (fingolimod), now the only MS therapy approved for pediatric patients in the U.S. That’s according to…

Frexalimab, a therapy Sanofi is developing for multiple sclerosis (MS) patients, led to sustained reductions in disease activity in people with relapsing forms of MS over more than two years of treatment, while continuing to show a favorable safety profile. That’s according to new data from an…

Consuming large amounts of ultra-processed foods (UPF) — products high in additives, artificial ingredients, and extensive processing — is associated with increased disease activity in people with clinically isolated syndrome (CIS), which is the first presentation of multiple sclerosis (MS), a study has found. The analysis used a…

Treatment with equecabtagene autoleucel, known for short as eque-cel — Iaso Biotherapeutics‘ CAR T-cell therapy candidate for people with progressive forms of multiple sclerosis (MS) — was well tolerated and led to an easing of disability for five patients taking part in a Phase 1 clinical trial. The…

Combining the diabetes medication metformin and the antihistamine clemastine significantly increased myelin repair in people with relapsing-remitting multiple sclerosis (RRMS), according to results from a Phase 2 clinical trial. However, the effects were small, and participants showed no improvements in disability or visual function after six months of treatment.

Increasing blood vitamin D levels with high-dose supplementation can significantly reduce the risk of new disease activity in people with clinically isolated syndrome (CIS), or those who experienced a first episode of symptoms suggestive of multiple sclerosis (MS). That’s according to new data from the D-Lay-MS…

Aerobic exercise may help promote myelin repair in some parts of the brain in people with multiple sclerosis (MS), according to a small study. Though the study included a small number of participants and followed them for a short period of time, the findings suggest that “supporting metabolic health…

Some older people with multiple sclerosis (MS), namely those older than 60, may be able to safely discontinue disease-modifying therapies (DMTs) as long as they continue to be regularly monitored for new disease activity, a new study suggests. The findings showed that people older than 50 generally experience an…

A stem cell transplant may offer better long-term results for people with aggressive multiple sclerosis (MS) compared with standard high-efficacy drug treatment, according to new evidence presented at a major European conference this week. Specifically, researchers found that an autologous hematopoietic stem cell transplant (aHSCT) was superior to…

People with multiple sclerosis (MS) seem to experience significant changes in cognition more than a year before significant physical decline is evident, a study found. While measures of processing speed, verbal memory, and visual memory worsened after about 2.7 years, significant changes in walking function and dexterity were only…

Following the MIND diet, a program that focuses on brain health, may help reduce disability, ease fatigue, and improve quality of life for people with multiple sclerosis (MS), according to an analysis of data from a U.K. database. The diet, which combines aspects of the Mediterranean and the Dietary…

The new revisions to the McDonald criteria for multiple sclerosis (MS) —  a set of guidelines long used to diagnose the neurodegenerative condition — have increased the proportion of people who can be diagnosed with MS and also allow for earlier diagnoses. That’s according to a new analysis…

The 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the world’s largest congress dedicated to multiple sclerosis (MS) research and care, kicks off today in Barcelona. About 9,000 scientists, clinicians, industry leaders, and patient advocates from more than 100 countries are expected…

Note: This story was updated Sept. 23, 2025, to correct the generic name of Aubagio from tolebrutinib to teriflunomide. The U.S. Food and Drug Administration (FDA) has delayed by three months its decision on whether or not to approve Sanofi’s tolebrutinib as a treatment for multiple sclerosis (MS),…

People with multiple sclerosis (MS) may receive less frequent treatments with anti-CD20 therapies without increasing their risk of disease activity or disability progression. That’s according to a new meta-analysis of published studies that investigated the use of different dosing schedules for anti-CD20 therapies — approved treatments that deplete the…

Doctors will be able to diagnose multiple sclerosis (MS) faster and with greater accuracy — allowing patients to access treatment and support earlier — following an update to the McDonald criteria, the official guidelines used to diagnose the condition. The revision reflects advances in understanding the biology of…

An international research team has secured nearly $800,000 (about CA$1.1 million) to advance a potential regenerative therapy for multiple sclerosis (MS) toward clinical testing. While existing treatments can slow disease progression, none can repair the nerve damage that has already occurred. This new project aims to change that by…

People with relapsing-remitting multiple sclerosis (RRMS) who started fasting or adopted a ketogenic diet — one low in carbs and rich in fat — for 18 months showed reductions in risk factors for heart and metabolic disease that were similar to those who followed a standard healthy diet, according…

Children and adolescents who go on to develop multiple sclerosis (MS) begin visiting the emergency department more often than their peers as early as a dozen years before their first MS symptoms appear, a new study from Canada suggests. In fact, over an 18-year period, children later diagnosed…

Paramagnetic rim lesions (PRLs), which represent areas of damage in the brain and spinal cord with chronic active inflammation, are highly indicative of multiple sclerosis (MS) in people being evaluated for the disease, a new study reports. The findings support using this imaging biomarker as a useful tool for…

A generic formulation of Zeposia (ozanimod), which won tentative approval for treating multiple sclerosis (MS) from the U.S. Food and Drug Administration (FDA), will be manufactured and supplied by Synthon, based in the Netherlands. Tentative approval means the generic version has met all FDA requirements for…

TG Therapeutics has started enrolling participants in a Phase 3 trial to test a new version of Briumvi (ublituximab-xiiy) that can be injected at home. This change could offer greater convenience and flexibility for people with relapsing forms of multiple sclerosis (MS). The new formulation is given…